An Anti-CD3 Antibody, Teplizumab, in Relatives at Risk for Type 1 Diabetes

Overview of attention for article published in New England Journal of Medicine, June 2019

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (99th percentile)
High Attention Score compared to outputs of the same age and source (98th percentile)

Mentioned by

news: 130 news outlets
blogs: 16 blogs
policy: 2 policy sources
twitter: 554 X users
patent: 36 patents
facebook: 16 Facebook pages

wikipedia: 9 Wikipedia pages
reddit: 9 Redditors
f1000: 1 research highlight platform
guideline: 6 clinical guideline sources
bluesky: 1 Bluesky user

Readers on

mendeley: 1040 Mendeley

So far, Altmetric has seen 1 Bluesky post from an account with 756 followers.

The T1D community has been down this road. They tested multiple weak but safer (often nutritional) interventions over several years, and all failed. When they got brave enough to try anti-CD3, they actually significantly delayed onset of autoimmune dise…

This page shows the most recent Bluesky posts that mention this research output. Click here to find out how to access more activity.